1. Generics Bulletin
  2. >>Products
  3. >>Generics

Elite Ships US Generic Adderall Amid Ongoing Shortages

Shortage Of Vital ADHD Drug Ongoing Since 2019

 
• By Chloe Kent

As the nationwide shortage of Adderall continues in the US, Elite Pharmaceuticals has announced the first shipment of its generic version to partner Prasco.

Adderall XR in an orange pill bottle
The Adderall shortage has been blamed on numerous factors, including increased demand and restrictive quotas • Source: Shutterstock

Specialty pharmaceutical company Elite Pharmaceuticals, Inc. has announced the first shipment of its generic Adderall (mixed amphetamine salts) to distribution and marketing partner Prasco Laboratories, LLC. Prasco is a non-exclusive US distributor of the drug, and will market it under the Burel Pharmaceutical label, while Elite will be responsible for manufacturing.

Key takeaways:

  • Elite has announced the first shipment of its generic Adderall to its distribution and marketing partner Prasco, which will market the drug in the US under the Burel Pharmaceutical label

  • Shortages of Adderall have been ongoing in the US for several years now, with a knock-on effect on other ADHD drugs

  • Multiple factors have been blamed for the

The generic is available in strengths of 5mg, 10mg, 15mg,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

More from Products

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”